Ithaka Life Sciences

Ithaka Life Sciences

Ithaka Life Sciences (Ithaka) provides expert advice, guidance, and hands-on support for organisations in the life sciences sector.

Telephone: 01223 703 146
Address: St. John's Innovation Centre, Cowley Road, Cambridge
Postcode: CB4 0WS
Country: United Kingdom
Website: http://www.ithaka.co.uk
Membership type:Professional Individual and Corporate < 5 (£50+VAT pa)

The Company’s team of industry experts works closely with companies ranging from SMEs to multinationals, universities and research organisations, investors, government agencies, the NHS and other public sector bodies to support them in the commercialisation of life science technologies.

Founded in 2000, Ithaka has delivered over 190 assignments for more than 90 clients, founded nine university spin-out companies, and helped early stage companies to raise in excess of £30m of investment finance.

Ithaka provides expert advice, guidance, and hand-on support for organisations in the life science sector. The services we provide include:

  • Technical, commercial and market evaluation of life science technologies
  • Commercial strategy: development and implementation from start up to exit, including exploitation of novel technologies and resources
  • Business creation and business plan drafting
  • Sourcing investment finance
  • Hands-on company management including CEO, business development and non-executive      director roles, as well as coaching and mentoring support for management teams
  • Business development, strategic marketing and licensing
  • Intellectual property review

The Ithaka team has particular in depth expertise in the following technology sectors:

  • Biomarkers and personalised medicine
  • Therapeutic proteins
  • Life science and biomedical research tools
  • Medical devices, diagnostics and sensors
  • Drug discovery and development
  • Agriculture and food

 

Ithaka Life Sciences' client CYP Design Ltd awarded Technology Strategy Board funding

Following the formation of CYP Design Ltd (CYPDESIGN™) by Ithaka Life Sciences and De Montfort University (DMU), Ithaka is pleased to announce that CYPDESIGN™ has been awarded a grant by the government-backed Technology Strategy Board - the UK’s innovation agency - to help support the development of new products and services, based on a set of proteins, named cytochrome P450s (CYPs).

9 January 2014Read in full

Ithaka Life Sciences client CYP Design awarded funding for research into novel antibiotics

Following the formation of CYP Design Ltd (CYPDESIGN™) by Ithaka Life Sciences and De Montfort University (DMU), Ithaka is pleased to announce that CYPDESIGN™ has been awarded funding by the Centre for Defence Enterprise (CDE) to help validate an automated platform for discovery of safe, effective, broad-spectrum anti-bacterial compounds.

18 November 2013Read in full

Ithaka Life Sciences client ProteinLogic awarded £1.2m TSB grant

Ithaka is pleased to announce that ProteinLogic, a biomarker discovery and exploitation company, Microtest Diagnostics, an in vitro diagnostic protein multiplexing company, and its collaborators have been awarded a grant by the Technology Strategy Board (TSB) to help support the development of MICROLOGIC™, a rapid point-of-care test for tuberculosis.

12 November 2013Read in full

Ithaka Life Sciences client CYP Design Ltd completes seed funding round

Following the formation of CYP Design Ltd (CDL) by Ithaka Life Sciences and De Montfort University (DMU|), CDL has completed a seed funding round led by Mercia Fund Management Ltd (MFM) under the Seed Enterprise Investment Scheme (SEIS).

22 October 2013Read in full

Ithaka Life Sciences' client ProteinLogic wins Med Tech award

Ithaka is pleased to announce that ProteinLogic, the biomarker discovery and exploitation company, was judged to have presented the strongest proposal in the Med Tech category to the Innovators’ Den at the NHS Healthcare Innovation Expo 2013 in London. Ithaka’s founder and Managing Director, Dr Paul Rodgers, is Executive Chairman of ProteinLogic.

25 March 2013Read in full

Ithaka Life Sciences' client ProteinLogic awarded Technology Strategy Board funding

Ithaka is pleased to announce that ProteinLogic, the biomarker discovery and exploitation company, has been awarded a grant by the Technology Strategy Board - the UK’s national innovation agency - to help support the development of a new diagnostic test for tuberculosis (TB). Ithaka’s founder and Managing Director, Dr Paul Rodgers, is Executive Chairman of ProteinLogic.

18 February 2013Read in full

Ithaka Life Sciences and De Montfort University spin out new drug discovery company

De Montfort University (DMU) has come together with a leading UK-based life sciences commercialisation company, Ithaka Life Sciences Ltd, to market new technology designed to speed up and reduce the cost of the development of new drugs and medicines.

17 January 2013Read in full

Paul Rodgers, MD of Ithaka Life Sciences, appointed as Chairman of ProteinLogic

Dr Paul Rodgers, Managing Director of Ithaka Life Sciences, the leading provider of consultancy and management services to new and growing life science businesses, has been appointed as Executive Chairman of ProteinLogic, the biomarker discovery and exploitation company.

5 October 2011Read in full

Ithaka Life Sciences renews successful contract with Scottish Enterprise

Ithaka Life Sciences, the leading provider of consultancy and interim management services to new and growing life science businesses, has had its existing contract with Scottish Enterprise extended to assist and advise life science research teams looking to move projects from the lab into the market place.

5 February 2009Read in full

Ithaka Life Sciences renews successful contact with Scottish Enterprise

Ithaka Life Sciences, the leading provider of consultancy and interim management services to new and growing life science businesses, has had its existing contract with Scottish Enterprise extended to assist and advise life science research teams looking to move projects from the lab into the market place.

4 February 2009Read in full

  1. 1
  2. 2